Lindsay Rosenwald - Fortress Biotech Chairman of the Board and Presidentident, CEO
| FBIOP Preferred Stock | USD 6.98 0.03 0.43% |
Chairman
Dr. Lindsay A. Rosenwald, M.D., is Chairman of the Board, President, Chief Executive Officer of FORTRESS BIOTECH, INC. Dr. Rosenwald has served as a member of the Board of Directors since October 2009 and as Chairman, President and Chief Executive Officer of the Company since December 2013. Dr. Rosenwald is currently CoChairman of the Board of Directors and Chief Executive Officer of CB Pharma Acquisition Corporationration, which he joined in 2014. Dr. Rosenwald also is CoPortfolio Manager and Partner of Opus Point Partners Management, LLC, an asset management firm in the life sciences industry, which he joined in 2009. Prior to that, from 1991 to 2008, he served as the Chairman of Paramount BioCapital, Inc. Over the last 23 years, Dr. Rosenwald has acted as a biotechnology entrepreneur and was involved in the founding and recapitalization of numerous public and private biotechnology and life sciences companies since 2013.
| Age | 68 |
| Tenure | 11 years |
| Professional Marks | Ph.D |
| Phone | 781 652 4500 |
| Web | https://www.fortressbiotech.com |
Lindsay Rosenwald Latest Insider Activity
Tracking and analyzing the buying and selling activities of Lindsay Rosenwald against Fortress Biotech preferred stock is an integral part of due diligence when investing in Fortress Biotech. Lindsay Rosenwald insider activity provides valuable insight into whether Fortress Biotech is net buyers or sellers over its current business cycle. Note, Fortress Biotech insiders must abide by specific rules, including filing SEC forms every time they buy or sell Fortress Biotech'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Lindsay Rosenwald over three months ago Acquisition by Lindsay Rosenwald of 1567515 shares of Fortress Biotech at 1.7 subject to Rule 16b-3 | ||
Lindsay Rosenwald over three months ago Acquisition by Lindsay Rosenwald of 10000 shares of Journey Medical at 3.04 subject to Rule 16b-3 | ||
Lindsay Rosenwald over three months ago Acquisition by Lindsay Rosenwald of 5000 shares of Fortress Biotech at 7.3942 subject to Rule 16b-3 | ||
Lindsay Rosenwald over three months ago Acquisition by Lindsay Rosenwald of 9728 shares of Journey Medical subject to Rule 16b-3 |
Fortress Biotech Management Efficiency
The company has return on total asset (ROA) of (0.3494) % which means that it has lost $0.3494 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.4338) %, meaning that it generated substantial loss on money invested by shareholders. Fortress Biotech's management efficiency ratios could be used to measure how well Fortress Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | CHAIRMAN Age | ||
| Michael Esq | Mustang Bio | 58 | |
| William Rice | Aptose Biosciences | 65 | |
Management Performance
| Return On Equity | -1.43 | ||||
| Return On Asset | -0.35 |
Fortress Biotech Pref Leadership Team
Elected by the shareholders, the Fortress Biotech's board of directors comprises two types of representatives: Fortress Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fortress. The board's role is to monitor Fortress Biotech's management team and ensure that shareholders' interests are well served. Fortress Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fortress Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lindsay Rosenwald, Chairman of the Board and Presidentident, CEO | ||
| Samuel Berry, Gen Sec | ||
| Robyn Hunter, Ex Officer | ||
| Michael Esq, Vice Devel | ||
| Thomas Schaible, Project Disease | ||
| George Avgerinos, Senior Vice President - Biologics Operations | ||
| David Jin, CFO Devel |
Fortress Preferred Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right preferred stock is not an easy task. Is Fortress Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Pair Trading with Fortress Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Fortress Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fortress Biotech will appreciate offsetting losses from the drop in the long position's value.Moving against Fortress Preferred Stock
| 0.47 | ZBIO | Zenas BioPharma, Common | PairCorr |
| 0.41 | CYCCP | Cyclacel Pharmaceuticals | PairCorr |
| 0.37 | EMMA | Emmaus Life Sciences | PairCorr |
| 0.37 | GRTX | Galera Therapeutics | PairCorr |
| 0.37 | HRGN | Harvard Apparatus | PairCorr |
The ability to find closely correlated positions to Fortress Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Fortress Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Fortress Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Fortress Biotech Pref to buy it.
The correlation of Fortress Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Fortress Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Fortress Biotech Pref moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Fortress Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Fortress Preferred Stock Analysis
When running Fortress Biotech's price analysis, check to measure Fortress Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fortress Biotech is operating at the current time. Most of Fortress Biotech's value examination focuses on studying past and present price action to predict the probability of Fortress Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fortress Biotech's price. Additionally, you may evaluate how the addition of Fortress Biotech to your portfolios can decrease your overall portfolio volatility.